The Management of Lithiasis

Urinary Tract Calculi: Introduction, Epidemiology, Etiology. 1. Urolithiasis: Composition, Symptoms and Pathology; A. Memon, J. Talati. 2. Radiology in Urolithiasis; S. Hussain. 3. Epidemiology of Urolithiasis in Pakistan; J. Talati, et al. 4. Urolithiasis in the Middle East: Epidemiology and Pathogenesis; S.R. El-Faqih, I. Hussain. 5. Epidemiology of Urolithiasis in the Western World; K. Hamawy, et al. 6. Metabolic and Dietary Risk Factors for Urolithiasis; R.A.L. Sutton, J. Talati. 7. Oxalate and Urolithiasis; R.A.L. Sutton. 8. Familial Clustering and Sex Incidence of Urolithiasis; J. Talati. Division 2: Choices in the Management of Calculi. 9. Decisions! Decisions! J. Talati. 10. Hazards of Open Surgery; J. Talati. 11. Choices, Limitations, Hazards and Value of Technology in the Treatment of Lithiasis; J. Talati. 12. Bioeffects of ESWL; J. Lingeman, F. Abbas. 13. Choices, Limitations, Hazards and Value of Technology: Laser Fragmentation of Urinary Calculi; G. Watson, T. Shah. 14. ESWL Today: The Spectrum of Stone Disease Treated on the Lithotriptor Today; J. Talati. 15. The Management of Renal Stones by Operation; J. Talati. 16. ESWL for Renal Stones and Management Options for Calyceal Calculi; J. Talati. 17. Percutaneous Nephrolithotony for Renal Stones; T. Shah, S. Hussain. 18. The Management of Staghorn Calculi; J. Talati. 19. Choices of Management of Ureteric Calculi; J. Talati. 20. Clinical Results of Laser Fragmentation of Ureteric Calculi; G. Watson, T. Shah. 21. The Management of Vesical and Urethral Calculi; Z. Hotiana. Division 3: Enhancement of Efficacy and Safety of Treatment. 22. Patients at Risk for Excessive Post-ESWL Bleeding; M. Khursheed, J. Talati. 23. Patients with Pacemakers; N. Baseer. 24. Safeguarding Fetus and Gonads; J. Talati. 25. Other High Risk Patients; J. Talati. 26. The Role of ESWL in Patients with Leprosy; G. Warren. 27. Factors Determining the Need for Multiple Treatments on the Dornier HM3; J.A. Belis, G. Halenda. 28. Factors Determining Need for Multiple Treatments: Decisions Based on Stone Bulk, Composition and Acoustic Efficiency; J. Talati. 30. Urinary Tract Infections, Stones and ESWL; J. Talati. 31. The Judicious Use of Stents; J. Talati, et al. 32. Protection of Hospital Personnel; J. Talati, S. Kahn. Division 4: High Technology at Affordable Cost. 33. Introduction: High Technology at Affordable Cost; J. Talati. 34. The Economics of Stone Therapy: An Economist's Views; S.K. Qureshi. 35. Selecting a Lithotriptor: Hospital Perspective; N.M. Khan, M. Dhanani. 36. Lithotriptor Sharing; R. Vleeming, et al. 37. Cost Factors in Equitable Care; J. Talati. 38. Commencing and Expanding Lithotripsy Services; J. Talati. 39. Financing a Lithotriptor; M. Kakalia. Division 5: Prevention of Urinary Tract Calculi. 40. Prevention of Urinary Tract Calculi; J. Talati. 41. The Residual Calcular Fragment; A Risk Factor For Recurrent Stone Disease; J. Talati. 42.